Suchergebnisse - "Yarchoan, Mark"

PubPharm (158)

1

Uncovering the spatial landscape of molecular interactions within the tumor microenvironment through latent spaces

enthalten in: bioRxiv.org | 2024

von Deshpande, A. | Loth, M. | Sidiropoulos, D. | +22

2

Spatial transcriptomics analysis of neoadjuvant cabozantinib and nivolumab in advanced hepatocellular carcinoma identifies independent mechanisms of resistance and recurrence

enthalten in: bioRxiv.org | 2024

von Zhang, S. | Yuan, L. | Danilova, L. | +11

3

First-in-human Phase I Trial of TPST-1120, an Inhibitor of PPARα, as Monotherapy or in Combination with Nivolumab, in Patients with Advanced Solid Tumors

enthalten in: Cancer research communications | 2024

von Yarchoan, M. | Powderly, J. | Bastos, B. | +17

4

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma : a phase 1/2 trial

enthalten in: Nature medicine | 2024

von Yarchoan, M. | Gane, E. | Marron, T. | +17

5

Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma

enthalten in: Nature reviews. Clinical oncology | 2024

von Llovet, J. | Pinyol, R. | Yarchoan, M. | +6

6

Predicting survival of patients with advanced hepatocellular carcinoma receiving combination targeted immunotherapy : an evaluation of volumetric imaging parameters

enthalten in: Abdominal radiology (New York) | 2024

von Mohseni, A. | Baghdadi, A. | Madani, S. | +9

7

Systemic Therapy for Advanced Hepatocellular Carcinoma : ASCO Guideline Update

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2024

von Gordan, J. | Kennedy, E. | Abou-Alfa, G. | +21

8

DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma

enthalten in: Cell reports. Medicine | 2024

von Kirk, A. | Crawford, J. | Chou, C. | +35

9

Critical Appraisal of Guideline Recommendations on Systemic Therapies for Advanced Hepatocellular Carcinoma : A Review

enthalten in: JAMA oncology | 2024

von Cappuyns, S. | Corbett, V. | Yarchoan, M. | +2

ErratumIn: JAMA Oncol. 2024 Jan 11;:. - PMID 38206599

10

Reply : The Hepa 1-6 may not be suitable for use in hepatocellular carcinoma models to explore responses to drug therapy

enthalten in: Hepatology (Baltimore, Md.) | 2024

von Zabransky, D. | Yarchoan, M. | Ho, W.

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[16]